NURIX THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
NURIX THERAPEUTICS INC. - More news...
NURIX THERAPEUTICS INC. - More news...
- Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
- Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
- Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
- Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
- Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
- Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
- Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
- Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
- Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
- Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
- Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
- Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
- Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
- Nurix Therapeutics Announces Presentations at Discovery on Target Conference
- Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
- Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
- Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
- Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
- Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
- Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
- Nurix Therapeutics Announces Board Chair Transition
- Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
- Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
